Drugs / BMN 333
last change Apr 2026 re-read 2 minutes ago

BMN 333

Developed for
achondroplasia
Investigated by
BioMarin Pharmaceutical

Trials 1 · a red edge is where a trial was stopped

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT07441876 Apr 2026 → Jun 2029 expected achondroplasia BioMarin Pharmaceutical Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BMN 333 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441876
Route Subcutaneous “Administration: Weekly subcutaneous injection” NCT07441876